2024-517354-98-00招募中2 期
Cytomegalovirus Prophylaxis with Letermovir in Heart Transplant Recipients: A Non-randomized Cohort Pilot Study
University Medical Center Ljubljana1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年9月17日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- The rate of early CMV infections/disease during virostatic prophylaxis.
研究概览
简要总结
The primary objective of the study is to investigate the efficacy of letermovir-based CMV prophylaxis in patients after heart transplantation.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •heart transplant recipient (new)
- •moderate (D+/R+ and D-/R+) or high (D+/R-) risk CMV serostatus
- •signed informed consent for participation in the study
- •age ≥ 18 years
- •not enrolled in competing clinical trials
排除标准
- •short-term mechanical circulatory support prior HTX
- •known hypersensitivity to letermovir
- •known hypersensitivity to valgancyclovir
- •known hematological disorders (apart from anemia)
- •history of malignancy (< 5 years; except adequately treated basal or squamous cell skin cancer or in situ cervical cancer) or under evaluation for active or suspected malignancy
- •advanced kindey disease (CrCL < 10 ml/min) at enrollment
- •advanced liver disease (Child Pugh Class C)
- •combined moderate kidney (CrCL < 50 ml/min) and liver (Child Pugh Class B) insufficiency at screening
- •concomitant administration with pimozide
- •concomitant administration with ergot alkaloids
- •concomitant administration with St. John’s wort (Hypericum perforatum)
- •multi-organ transplantation
- •concomitant administration of cyclosporine
- •concomitant use of dabigatran, atorvastatin, simvastatin, rosuvastatin or pitavastatin is contraindicated
- •known hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
- •combined hepatic and renal impairment
- •HIV infection
- •Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or put the participant at undue risk, as judged by the investigator, such that it is not in the best interest of the participant to participate in this study
- •Has previously participated in this study or any other study involving letermovir.
- •Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study.
- •ongoing CMV infection/disease
- •D-/R- CMV serostatus
- •heart re-transplantation
- •need for intensified immunosuppression protocol (>20% cytolytic alloantibodies prior transplant or perioperative (within 7 days after HTX) allograft rejection > 1R)
- •immunoinduction with ATG
- •active participation in another interventional clinical trial
结局指标
主要结局
The rate of early CMV infections/disease during virostatic prophylaxis.
The rate of early CMV infections/disease during virostatic prophylaxis.
次要结局
- •The rate of leukopenia during virostatic prophylaxis
- •The rate of neutropenia during virostatic prophylaxis
- •The rate of late CMV infections/disease between virostatic discontinuation and 6 months thereafter.
- •The time-course of the restitution of cell-mediated immunity during virostatic prophylaxis
- •The rate of CMV resistance to virostatic therapy.
研究者
Bojan Vrtovec
Scientific
University Medical Center Ljubljana
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabB-Cell Prolymphocytic LeukemiaPeripheral T-Cell LymphomaPrimary Cutaneous T-Cell Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaSezary SyndromeT-Cell Prolymphocytic LeukemiaNCT04312841Ohio State University Comprehensive Cancer Center6
招募中
3 期
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric PatientsHematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmNCT05711667Children's Oncology Group105
招募中
不适用
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBTCytomegalovirus Infection ReactivationNCT06441669Anhui Provincial Hospital60
已完成
2 期
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) InfectionCMVCMV InfectionHematopoietic Cell TransplantNCT04017962Memorial Sloan Kettering Cancer Center102
尚未招募
4 期
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCTThe Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After TransplantationNCT05914675Institute of Hematology & Blood Diseases Hospital, China21